Affiliation:
1. Department of Gynecology, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Institute and
Hospital), No. 44, Xiaoheyan Road, Shenyang, 110042, Liaoning Province, China
2. Central Laboratory, Cancer
Hospital of Dalian University of Technology (Liaoning Cancer Institute and Hospital), No. 44, Xiaoheyan Road,
Shenyang, 110042, Liaoning Province, China
Abstract
Background:
Ovarian cancer is the second most common cancer to cause large death
among gynecological tumors. Paclitaxel is important to the standard treatment for epithelial ovarian
cancer. Due to its low solubility and permeability, nano-paclitaxel came into public view.
Objective:
To evaluate the effect of nano-paclitaxel in ovarian cancer.
Methods:
Considering the importance of bevacizumab in clinical treatment, we set four groups for
research: control, paclitaxel, paclitaxel + bevacizumab, and nano-paclitaxel + bevacizumab. CCK-8,
apoptosis, and cell cycle assays were used to detect the cell survival condition. qRT-PCR and western
blot were used to detect the gene mRNA and protein expression level. Tumor xenograft in nude
mice was used to detect the effect in vivo.
Results:
The nano-paclitaxel combined with bevacizumab had the best curative effect. Moreover, the
downstream indicators, such as caspases, BAX, FAS, OGFr, PD-L1 and VEGF, changed in four
groups, which suggested that the therapy worked by affecting the cell apoptosis, cell cycle, angiogenesis,
and immune reaction.
Conclusion:
In conclusion, the study helped us better commandof nano-paclitaxel for ovarian cancer
treatment and thus could play a role in OC therapy.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Biotechnology